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ABSTRACT
Awoyemi, Azeezat Afolake. M.S. Department of Pharmacology and Toxicology,
Wright State University, 2018. Regulation of Microvesicle Particle release in
keratinocytes.

Microvesicle particles (MVPs) are produced from cellular membranes and are thought
to mediate cell-cell communication, including in response to stressors such as UVB
radiation and thermal burn injury. Previous studies have shown that stress-induced
MVP release requires the platelet-activating factor (PAF) receptor in human
keratinocytes and that pharmacological inhibition of acid sphingomyelinase (ASM)
blocked this release. To validate a genetic role for ASM in MVP release, we used
CRISPR-Cas9 gene silencing in human keratinocytes and primary fibroblasts derived
from ASM-knockout mice. Though MVP release was partially blocked in ASMdeficient mouse fibroblasts, the inability to fully knockdown ASM in HaCaT cells
resulted in no significant impact on MVP production. We also found that ethanol, which
is known to augment PAF production, stimulated MVP release in human keratinocytes
and in mice in vivo. These studies therefore provide additional insights into the role of
ASM and ethanol in MVP release.
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CHAPTER 1: INTRODUCTION

1.1

Statement of Problem
Microvesicle particles (MVPs) play a significant role in pathological processes

by transmitting mechanistic signals from secretory cells to recipient cells in both the
healthy and disease state. MVPs are potential biomarkers and could be exploited for
diagnostic or therapeutic uses. Given that our group’s previous studies have provided
evidence that various environmental stressors generate MVP in skin keratinocytes, an
improved understanding of MVP regulation by the enzyme acid sphingomyelinase and
testing the ability of the polar solvent ethanol to modulate release of these subcellular
particles are the two problems this project was designed to address.

1.2

Significance
The significance of these studies is that MVPs may play important roles in how

keratinocytes respond to environmental stressors. Thus, the regulation of MVP release
could provide new targets to treat injuries from UVB and thermal burn. Moreover, our
group has implicated the lipid mediator Platelet-activating factor (PAF) in how
environmental stressors interact with skin, as well as how ethanol can augment
environmental stressor effects. For example, studies have shown that the intoxicated
state of people who are exposed to thermal burn result in increased morbidity and
mortality that those without prior exposure [1]. Thus, these studies can provide
important and clinically-relevant insights into how the skin responds to external
stressors.
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1.3 Statement of Purpose
The aims of this study are two-fold. First, we will attempt to verify whether the
genetic knockout of ASM decreases MVP release upon exposure to thermal burn injury
and UVB radiation in keratinocytes. Does treatment of ASM KO cells with C2ceramide increase MVP? Does treatment of HaCaT cells, WT and PAFR-KO mice with
EtOH, burn and EtOH + Burn increase MVP release? Does treatment of HaCaT cells
with CPAF cause translocation of ASM from the nucleus to the cell membrane? Does
ethanol exposure modulate MVP exposure, either in keratinocytes in vitro or in mice in
vivo?

1.4

Hypothesis
Our hypothesis is that the knockout of ASM in mammalian cells will inhibit the

production of MVPs upon exposure to stressors in comparison to wild type cells. We
also predict the translocation of ASM from the nucleus to the membrane after treatment
with CPAF.
We expect that HaCaT cells treated with ethanol and later exposed to thermal burn
in a time dependent manner will result in augmented MVP release. We expect that
PAFR-KO mice will result in a decreased MVP release in comparison to WT mice upon
treatment with ethanol plus thermal burn both from skin as well as in serum.
Null Hypothesis
Ho: µØ= µC= µU= µB: The mean release of MVP in group without treatment is equal to
the mean release MVP of CPAF, UVB and Burn groups of ASM-KO HaCaT cells
Ha: Not all means of release of MVP are the same.
1. Null Hypothesis
2

Ho: µØ= µC= µU= µB: The mean release of MVP in WT NMF group is equals to
the mean release MVP of CPAF, UVB and Burn groups of ASM-KO
NMF
Ha: Not all means of release of MVP are the same.
2. Null Hypothesis
Ho: µØ= µE= µB= µE+B: The mean release of MVP in group without treatment is
equals to the mean release MVP of EtOH, TBI and EtOH+ TBI groups
of HaCaT cells
Ha: Not all means of release of MVP are the same.
3. Null Hypothesis
Ho: µØ= µE= µB= µE+B: The mean release of MVP in group of WT mice is equals
to the mean release MVP of EtOH, TBI and EtOH+ TBI groups of
PAFR-KO mice
Ha: Not all means of release of MVP are the same.
4. Null Hypothesis
Ho: µØ= µC: The mean release of MVP in group without treatment is equals to
the mean release MVP of CPAF groups of HaCaT cells
Ha: Not all means of release of MVP are the same.

1.5

Research Objectives
 To develop a genetic approach to study the role of ASM in MVP release in
response to CPAF, thermal burn injury and UVB irradiation in mammalian
cells.
 To determine if EtOH increases MVP release in keratinocytes
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 To determine if exposure to EtOH prior to thermal burn injury causes increase
in MVP release in vitro and in vivo.
•

To test if there is increase MVP release systematically on exposure to
EtOH and thermal burn injury in vivo.

 To test the translocation of ASM to the membrane in keratinocytes upon
treatment with CPAF.

1.6

Abbreviations
✓ ASM: Acid Sphingomyelinase
✓ C2: C2 Ceramide
✓ CAS9: CRISPR-associated proteins
✓ CPAF: Carbamoyl-PAF
✓ CRISPR: Clustered, regularly interspaced short palindromic repeats
✓ DMEM: Dulbecco's Modified Eagle Medium
✓ DMSO: Dimethyl sulfoxide
✓ di- C2: C2 Dihydroceramide (N-acetoyl-D-erythro-sphinganine)
✓ EtOH: Ethyl Alcohol (C2H5OH)
✓ gRNA: guide Ribonucleic Acid
✓ HaCaT: Human Keratinocyte cell line
✓ HBSS: Hanks’ Balanced Salt Solution
✓ HR: Homologous Recombination
✓ KO: Knockout
✓ MVP: Microvesicle particle
✓ NHEJ: Non-homologous end joining
✓ NMF: Normal Murine Fibroblast

4

✓ PAF: Platelet Activating Factor
✓ PAF-R: Platelet Activating Factor Receptor
✓ PAM: Protospacer Adjacent Motif
✓ PBS: Phosphate Buffered Saline
✓ ROS: Reactive Oxygen Species
✓ TBI: Thermal Burn Injury
✓ UVB: Ultraviolet B radiation
✓ WT: Wild Type

1.7

Assumptions

We made the assumption that keratinocytes and fibroblasts respond in the same manner
as to when in the whole-body system when exposed to different treatments. In addition,
we made the assumption that mice will react the same upon treatment irrespective of
the gender of the mice.
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CHAPTER 2: LITERATURE REVIEW

2.1

Microvesicle Particles
Microvesicle particles are small spherical shaped particles of 100-1000 nm in

diameter [2,3] that bleb directly from the plasma membrane of various cell types such
as epithelial cells, neutrophils, tumor cells, macrophages and monocytes [4]. This
process might be as a result of the beginning of apoptosis [3,4], upon serum deprivation
[5] or activation by internal or external stimuli which causes increases in the level of
intracellular calcium and results in MVP release from the plasma membrane [4]. MVPs
were earlier referred to as platelet dust [6], but were later shown that they carry various
bioactive substances including signalling proteins, bioactive lipids, cytokines,
chemokines and nucleic acids, enzymes, and growth factors [3]. On exposure to
external stimuli such as TBI, UVB, or cigarette smoke, MVP are thought to contain
bioactive substances. Signals are mediated by MVP thus by promptly transferring these
biological substances from a parent cell, either in an healthy state or diseased state
(MVP shed from cancerous cells may promote spreading of oncogenes)

to

neighbouring cells and to cells far-off from the parent cell [3].
There are several signalling pathways by which particles can be released and
this depends on the trigger agent on the membrane of the cell. For example when an
endothelial cell is triggered by thrombin and angiotensin II, the RhOa-ROCK pathway
is required [5]. Furthermore, the p38-MAP kinase pathway is needed for particle release
when triggered by TNF- α [5] and this process can be blocked by adding inhibitors of
the pathways involved in both processes. MVP role in cell to cell communication has
6

made it a point of interest as a potential tool for therapy, prevention and biomarker of
several diseases [3].

2.2

Keratinocyte Damage
Human skin is one of the largest organs in the body, and epidermal keratinocytes

have direct regular exposure to environmental and external stressors because they are
on the outermost part of the skin. These external stimuli can include ionizing radiation,
harmful chemicals, toxins, contaminants and O3 being the most hazardous [7].
Keratinocytes are largely affected by pro-oxidative stress caused by UV radiation and
heat shock [8]. These stressors penetrate the skin barrier causing photo-peroxidation of
cellular lipids, production of ROS and damage to cellular DNA [9], which could result
in neoplastic tumor formation. Excessive exposure to prolonged oxidative stress can
overpower the endogenous protective system consisting of both enzymatic and nonenzymatic processes thus causing damage to the skin [7]. It is essential to both
understand the effects of and decrease levels of ROS caused by external factors to avoid
perpetual damage to cellular system [8] and production of inflammatory cytokines.
Topical application of resveratrol (a plant polyphenol) can protect the human
keratinocyte by inhibiting the formation of cigarette smoke induced ROS and carbonyl
development thus acting as a good defensive mechanism [10]. Therapeutic mediation
using antioxidants and PAF receptor antagonists is a key approach to lessen the photooxidation that occurs upon cutaneous inflammation [9].
2.3

PAF-Receptor
Platelet Activating Factor (1-alkyl-2-acetyl glycerol-phosphocholine) is an

inflammatory phospholipid that carries out its action through a G-protein coupled
transmembrane receptor, known as PAF-Receptor (PAF-R) that is found on multiple
7

types of classically immune cells as well as epidermal skin cells [11]. Both PAF and
oxidized glycerol-phosphocholines exert agonistic actions on the PAF-R. Pro-oxidative
stressors such as jet fuel, chemotherapy agents, cigarette smoke, and UVB all generate
ROS that acts upon glycerophosphocholines (GPC) immediately to form oxidized GPC
(ox-GPC) which are have strong agonistic effects on PAF-R [12]. Binding of PAF to
its receptor activates different second messenger systems, including mitogen-activated
kinases, protein kinase C, nuclear factor kappa B pathways, phospholipases, and
prostaglandin-generating cyclooxygenase enzymes [13,14]. Activation of this receptor
by external stimuli also prompts PAF to be synthesized via enzymatic process
indicating a potential feed-forward system [14].
Previous studies have implicated PAF in how keratinocytes generate MVP.
PAF agonists generate MVP, and UVB-mediated MVP release requires PAF-R
receptor signalling by exposing KBP and KBM cells (KBP cells express the PAF-R
but KBM cells do not) to UVB and found that only KBP cells released MVP
compared to KBM cells [11]. Thus, that the PAF-R plays a role in UVB-mediated
MVP release.

2.3.1 Role of PAF and PAF-R in Keratinocyte Damage
Ultraviolet B radiation (UVB) exerts profound effects on human epidermis and
carries out its action by activating bioactive substances and lipids in keratinocytes
[14,15] and is a common cause of skin cancer [16]. Stimuli including cytokines,
endotoxins and Ca+ ionophores activates rapid PAF synthesis. Keratinocyte damages
by thermal burn or cold increments causes an increase in PAF being generated [14].
Epidermal cell exposure to UVB might be a process in which signals are transmitted to
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the system [11]. UVB-stimulated acute inflammation enhances the formation of
cytokines such as TNF-α [15] and IL-10 [17] through activation of PAF-R. TNF-α
formation mediated by UV radiation in epithelial skin cells is linked to inflammation
and epidermal cell death has been implicated in UVB-induced inflammation and
epidermal cell apoptosis [15]. The PAF system is associated with keratinocyte function
and skin inflammatory diseases [18]. PAF-R activation causes production of
prostaglandins, IL-8 and COX-2, the latter of which is involved in epidermal
carcinogenesis [15,17]. Studies carried out by Yao et al. revealed that antioxidants
vitamin C, N-acetylcysteine and the pharmacological inhibitor PD168393 distinctive
for the epidermal growth factor receptor blocked UVB-induced ROS and agonists of
PAF-R [16].

2.4

Acid Sphingomyelinase
Acid sphingomyelinase is an enzyme involved in catalysing the cleavage of

sphingomyelin to ceramide and phosphorylcholine. ASM has an optimum pH of 5.0
[19] and molecular size of 70 kDa [20]. Deficiency of this enzyme has been associated
with the rare autosomal recessive disorder Niemann-Pick disease [21] thereby causing
skin and neural defects by a pathologic accumulation of sphingolipids in cells and
tissues. Earlier studies have shown that ASM is localized in the secretory vesicles on
plasma membrane [22]. Upon stimulation, ASM translocates from lysosomal
intracellular storage to the outer leaflet of the cell membrane thereby releasing ceramide
[23]. Activation of cells triggered by mediating stressors such as PAF, thrombin,
amyloid [24], ionizing radiation (IR) [22], by triggering ASM thereby inducing
ceramide formation thus causing cell apoptosis and thereby adding to pathophysiology
of several diseases. Ceramide can also be produced based on the trigger or type of cell
9

via a (SMase)-dependent catabolism of sphingomyelin (SM), a de novo synthetic
pathway or a salvage synthetic pathway [22].
ASM plays a major role in the secretion of T-lymphocyte granules,
degranulation, vesicle blebbing, and MVP release from glial cells [24]. ASM is
essential in lipid communication in heart diseases thus causing inflamed vasculature
[24]. ASM facilitated ceramide production takes place rapidly and is mainly localized
in the plasma membrane [22] thereby stimulating quickly activating cellular functions
on activation of the cells [24] and playing a main role in generating pulmonary edema
associated with acute lung injury. Studies shows that weak bases prevents ASM activity
[19]. Tricyclic anti-depressants such as imipramine, desipramine, and amitriptyline are
known to inhibit the function of ASM activity [19] and mitigate receptor-stimulated
cell death, apoptosis mediated by cell response to stress stimuli enhance to proliferate
due to their anti-cell death effect. Thus, ASM inhibitor may be useful for therapy in
diseases such as inflammatory bowel disease and acute lung injury thereby curbing
LPS-stimulated inflammatory cytokine release from macrophages [19].

2.4.1

ASM and MVP
Bianco et al. proposed a model of P2X7R mediated MVP blebbing

processes by the translocation of MVP to the plasma membrane by recruiting ASM
activity in glial cells. When the P2X7 receptor is activated, it stimulates the action of
ASM via agonism of the P2X7 receptor pathway such as ROCK [25] and p38 MAP
kinase activation necessary for MVP formation and release. An important component
of MVP shedding is extracellular Ca2+ flux which occurs very rapidly [15,16]. A kinetic
study of MVP blebbing revealed that they are rapidly released in 5 minutes and
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maximal by 20 minutes upon P2X7 receptor activation [26]. Inflammatory cytokines
like IL-1β accumulate in MVPs from microglia and are released upon stimulation of
P2X7 receptor. The released MVP are involved in cell to cell release of signalling
molecules and dissemination of information via several means of secretion and are also
known to play an essential role in immune reactions.

Figure 1: Mechanism of MVP blebbing initiated by activation of P2X7R and
engagement of ASM [26].
2.5

Ethanol
One of the most abused substances and leading causes of death worldwide is

ethanol (EtOH) [27,28]. Upon exposure to EtOH, ASM activity is activated thereby
increasing the level of ceramide [29] and in vitro treatment of hepatocytes with EtOH
led to a decrease in sphingomyelin and a rise in ceramide levels [30]. Kupffer cells
produces TNF-α upon exposure to EtOH, and this cytokine has been identified as a
stimuli for ceramide secretion through the stimulation of ASM [31]. Augmented levels

11

of ASM have been implicated in many pathological conditions including alcoholism
[32].
Studies have shown that the treatment of hepatoma cells with EtOH had a major
increase in cellular ceramide content by 20% [33]. It has been reported in vivo that ASM
is activated by EtOH with a resultant increase in the level of cellular ceramide [29].
Treatment of hepatoma cells and mice with EtOH decreased the action and level of
AMP Kinase, which is known to control lipid metabolism [18,19] and result in a
stimulation of fatty acid synthesis. The phosphorylation of AMP Kinase by EtOH is
reported to be overturned using imipramine, thus suggesting that the production of
ceramide through ASM is activated by EtOH [33].

2.5.1

Ethanol and TBI
Thermal burn injury is life-threatening health trauma in the world with several

cases being reported daily. About 50% of burn patients hospitalized had alcohol in
their system when they were exposed to thermal injury and studies revealed that patients
with alcohol in their blood stream prior to thermal injury have a 3 to 6-fold increased
risk of death [1]. Thermal injury to the skin brings about the degeneration the of lining
of intestinal membranes thereby inducing bacterial translocation leading to infections
and several organ failure in individuals affected [34]. Prior exposure of individual to
alcohol causes higher rate of injury and death. Studies have shown that in mice
experiments, ethanol and TBI causes systemic toxicity observed in human having organ
failure, acute systemic production and delayed immunosuppression [35].
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2.6

Translocation of ASM
ASM is primary located in the nucleus of the cell, however upon exposure to

external stimuli such as UV light [36], H2O2 [37], Pseudomonas aeruginosa, ASM
translocates to the outer leaflet of the plasma membrane and is highly dependent on
Ca2+ levels [37]. It has been shown that lysosomes move and fuse to the plasma
membrane in reaction to increased intracellular Ca2+ [38]. The method by which Ca2+
independently translocates ASM is not well known, but may involve activation of
PKCδ by ROS when then interact with vesicles having ASM which is then externalized
to the plasma membrane [39]. Confocal analysis of ASM build-up on the surface of the
cell was identified as soon as ten minutes of exposure to UVC light and increased at
twelve minutes which was reduced to normal level after fifteen minutes as fluorescence
signal subsides [36].

2.7

CRISPR CAS9
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-

CRISPR associated protein 9 (Cas9) technique, is an effective systemic tool for genetic
engineering in biological research which has initiated a new era of genome editing by
overcoming the limitations of earlier methods [40]. In 1987, a research group from
Japan were the first to illustrate CRISPR in E. coli as an odd 29-nucleotide repeat
sequence including 32-nucleotide spacing [41].
This systematic tool requires guide RNA (gRNA) which directs the Cas9
endonuclease to the location of double stranded DNA (ds-DNA) sequence of interest
to make cuts in the DNA that are then repaired by either NHEJ or HDR-systems to edit
the genome [42,43]. Protospacer Adjacent Motive (PAM) helps to modify double
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strand break by enabling Cas9 to cut gRNA target to enable a straight transcript
recognition in a map out way [44]. HR has been developed to manipulate gene of
interest by creating KO and knock-in in vitro and in vivo models [45,46]. On the other
hand, NHEJ develops random or by-chance insertion and deletions producing a
frameshift mutation, however availability of exogenous donor DNA template around
double strand break can repair damage to the DNA through HDR mechanism thereby
accurately modifying gene or creating insertion of gene at a point of interest [47].
In the past several years, CRISPR Cas9 has been successfully used in research
to modify many different organisms and to develop in vitro and in vivo models [48,49]
and improvement of several diseases in humans. This biological tool has potential in
the treatment of sickle cell disease, correcting HBB gene mutation through homologous
direct recombination thereby normalizing production of red blood cells [47]. However
plenty of work is still required by scientific investigators to solve and eliminate
pathogen carrying species such as malaria, Zika virus, and aid drug production [50].
Scientists have successfully demonstrated zebrafish models [51] and in vivo genetic
models using CRISPR Cas9.
CRISPR Cas9 technology continues to develop as a potential therapy for use in
many genetic disorders through a safe and regulated gene therapy.
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CHAPTER 3: Materials and Methods

3.1

Introduction
This chapter discusses the model systems, procedures, and analysis performed to

acquire the relevant data to answer the experimental questions of this study. Two model
systems were utilized in the studies that were carried out: in vitro human and mice cell
lines and an in vivo mouse model.

3.2

Cells and Cell culture
HaCaT cells are nontumorigenic cells derived from the formation of

spontaneously immortalized human skin keratinocytes with its normal epidermal
phenotype maintained (1), N-TERTs (telomerase-immortalized normal human
keratinocytes), Normal Mice Fibroblasts (NMF) were from the skin of 2-day old WT
and ASM-KO mice pups by first removing the epidermis with dispase and then
treatment of the dermis with collagenase [53].

3.2.1

Cell growth media and storage condition
Both HaCaT cells and NMF were grown in Dulbecco’s modified Eagle’s

medium, (DMEM Hyclone, Logan, UT) and supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT), 100 U penicillin/ 0.1 mg/mL streptomycin (1%), 2 mM
glutamine (1%) and incubated at 37°C and 5% CO2 in a humidified incubator.
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3.2.2

Cell passage
Prior growth media were discarded from cells and plates were washed with 1x

PBS followed by addition of 2 mL 0.25% Trypsin-EDTA 1X to the HaCaT cells with
10-15 minutes incubation and 2 mL 0.05% Trypsin-EDTA 1X was added to plates
containing NMF and incubated for less than 5 minutes in the incubator. After the
stipulated time both incubation, 8 mL of growth media was added, cells were
resuspended using a 10 mL pipette. Resuspended cells were added to fresh growth
media in 10 mL cell culture corning plate at a ratio of 1:10.

3.2.3

Cell count
Cells count was derived from resuspended cells during passage, 200 µL of

passaged cells and 800 µL of PBS 1x were added into a 1.5 mL microfuge tube. Cell
number was determined using a Millipore Scepter handheld automated cell counter.

3.3

Treatments
2.5 mL of HBSS+ BSA (lipid free) per 10 cm plate to the cells in each treatment

group.
Table 1 : Treatment groups
Treatments

Concentration/ Time

No treatment

Ø

Sham

0.1% EtOH

EtOH

1% EtOH

PMA

100 nM
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UVB

3.6 KJ/m2

Thermal burn (90°C)

8s, 45s

CPAF

100 nM

After treatment, HaCaT cells were incubated at in a humidified incubator at 37°C for 4
hours.

3.4

MVP Isolation
On completion of the study design incubation period, 2 mL of the HBSS +BSA

was pipetted out from each treatment group into 2 mL microfuge tubes. These were
thereby balanced accordingly into Eppendorf® centrifuge 5810R firstly at 2,000 x g for
20 minutes at 4°C. Secondly, after centrifugation was completed, the supernatant was
then carefully transferred into new 2 ml microfuge tubes and centrifuged at 20,000 x g
for 70 minutes at 4° C. The supernatant was then discarded, and the MVPs were
resuspended in 100 µL of filtered 1x PBS. The concentration of MVP was measured
with appropriate dilution using Nanoparticle Tracking Analysis (NTA) software
version 3.0.

3.5

MVP Analysis
Results obtained from each sample using the NanoSight NTA software version

3.0 were multiplied by the dilution factor to get the concentration, which was then
divided by the cell number and multiplied by 100,000 cells. GraphPad Prism was used
to graph the result with ANOVA and S.E.M. obtained with a confidence interval of 95
%.
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3.6

Mice
C57BL/6 EGFP Wild type mice were obtained from Indiana University–Purdue

University Indianapolis (IUPUI) from Dr. Travers colony and were commercially
obtained from JAX. Mice were housed together, provided with water and food ad
libitum in a 12-hour light/dark cycle room. The protocol for experimental use of animals
was approved by Wright State University, School of Medicine’s Laboratory Animal
Care and Use Committee (LACUC).
SMPD1+/- heterozygous mice were obtained from Dr. Irina Petrache’s group at
National Jewish Medical Center in Denver Colorado. The mice were quarantined and
housed together. They were provided with food and water ad libitum in a 12-hour
light/dark cycle room. The protocol for experimental use of animals was approved by
Wright State University, School of Medicine’s Laboratory Animal Care and Use
Committee (LACUC). Acid sphingomyelinase knockout mice (SMPD1 -/-), wildtype
littermates (SMPD1 +/+) and heterozygous littermates (SMPD1 +/-) were generated
and bred. Pups produced were genotyped by polymerase chain reaction (PCR).
PAFR KO mice were obtained from Indiana University–Purdue University
Indianapolis (IUPUI) from Dr. Travers colony and were obtained originally from
Professor Shimizu from the University of Tokyo. Mice were housed together, provided
with water and food ad libitum in a 12-hour light/dark cycle room.
All mice were 6-8 weeks old for these studies.

3.6.1

Treatment
Each mouse (WT and PAFR-KO) was weighed and treated in mL/kg according

to its weight. The mice were anaesthetized by injecting them with Ketamine/ Xylazine
(Intraperitoneally, IP). The mice were shaved on their back using a clipper and
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buprenorphine was administered SUB-Q to prevent pain. Experimental groups were
sham, EtOH, thermal burn and EtOH + thermal burn. Mice were given EtOH or saline
(IP) and 30 min later given thermal burn, as determined by group. The mice were
exposed to thermal burn for 8 seconds using a 2 cm by 2 cm stainless steel iron already
heated at 90° C in a water bath. Yohimbine was administered to mice to reverse the
effects of anaesthesia and given 0.5 mL warm normal saline. The mice were then
returned to their individual cages for 2 hour following treatments.

3.6.2

Blood sample collection
After 2 hours, mice were euthanised in a CO2 tank and cervically dislocated.

Blood was then drawn from each mouse using a 1ml 30 g BD- syringe and transferred
to an Eppendorf tube. The blood was left to coagulate for 30 minutes and then
centrifuged at 15000 g for 15 minutes. The serum (upper clear layer) was then carefully
pipetted into a new tube.

3.6.3

Mice skin punch biopsies
Biopsies were taken from mouse skin using 6 mm disposable biopsy punches

(Integra Miltex) and were placed in separate Eppendorf tubes. A biopsy from the area
of thermal burn and unburnt area (stomach area) was kept in formalin for histology, and
other biopsies (3) for MVP analysis and a biopsy stored in RNA later for PCR.

3.6.4

MVP extraction
Five mg/mL collagenase/dispase in 1:1 H2O was added to each tube needed for

MVP analysis. The skin biopsies were then cut into small pieces and left for overnight
digestion in a shaker at 37°C. The tissue was then centrifuged at 20,000 x g for 10
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minutes, and supernatant was then transferred to a new tube and then centrifuged at
70,000 x g for 10 minutes to remove pellets. Supernatant was transferred to a new tube
and centrifuged at 70, 000 x g for 70 minutes. After centrifugation, the supernatant was
then discarded, and MVPs were resuspended in 100 µL of filtered 1x PBS. The
concentration of MVPs was measured with appropriate dilution using Nanosight (NTA
software version 3.0.).

3.6.5

MVP Analysis
Results obtained from each sample using NTA software version 3.0 was

multiplied by the rate of dilution to get the concentration, this is then divided by the cell
number and multiplied by 100,000 cells. GraphPad Prism was used to graph the result
with ANOVA and S.E.M. obtained with a confidence interval of 95 %.

3.7

CRISPR/CAS 9 Knockout of Acid Sphingomyelinase gene
Commercial CRISPR/CAS 9 knockout kits for targeting human ASM were

purchased from ORIGENE® The kit had two gRNA vectors, a scramble negative
control and a donor vector [54].

3.7.1

Super competent bacterial transformation
Aliquots of competent bacteria stored at -80°C were obtained and thawed on

ice. Five ng of donor vector plasmid was added to 50 L of the competent bacteria and
then incubated on ice for 10 minutes. The tube was then placed in a 42°C water bath
for 40 sec and transferred back on ice for another 15 minutes. A 2 mL LB was
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transferred to a glass tube and the prepared bacteria and plasmid was placed in it and
incubated on a shaker at 37 °C for 1 hour 30 minutes. 100 L of the solution was added
to agar plate containing 50 g/ mL ampicillin spread using a streak plate. It was then
incubated overnight at 37°C. The colonies were taken and placed in 120 mL Lysogeny
broth (LB) broth containing 100 g/mL Ampicillin. After this, plasmid DNA was
purified using GeneJet kit (Thermo Fisher Scientific).

3.7.2

Enzyme restriction

Agarose gel of 0.4g was weighed and mixed with 40 mL of TAE in a 100 mL
conical flask. It was then placed in a microwave until agarose dissolved, then 4 L of
10 mg/ml ethidium bromide was added, allowed to cool a little, poured into a gel
cassette, comb was inserted and allowed to cool.
Table 2: Treatment: gRNA 1& 2 (8022 base pair)
Label

DNA

tubes

NEB

PshA1

SacII

buffer 4

PshA1&

H20

SacII

PshA1

2L

1L

1L

-

-

6 L

SacII

2L

1L

-

1L

-

6 L

PshA1&

2L

1L

-

-

1L

6 L

2L

1L

-

-

-

7 L

SacII
Blank

Table 3: Treatment: pCas-scramble (8022 base pair)
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Label

DNA

tubes

NEB

PshA1

SacII

buffer 3

PshA1

2L

1L

SacII

2L

1L

PshA1 & 2L

1L

1L

PshA1 & H20
SacII

-

-

6 L

1L

-

6 L

-

-

1L

6 L

-

-

-

7 L

1L

SacII
Blank

2L

Table 4: Treatment: Donor Plasmid (7020 base pairs)
Label

DNA

tubes

NEB

PshA1

SacII

buffer 3

PshA1

2L

1L

SacII

2L

1L

PshA1 & 2L

1L

1L

PshA1 & H20
SacII

-

-

6 L

1L

-

6 L

-

-

1L

6 L

-

-

-

7 L

1L

SacII
Blank

2L

2 L of bromophenol blue (6x) was then added to each tube. 6 L of these solutions
was the loaded into electrophoresis tank and run for 50 mins at 100 volts. The gel was
then visualized under UV light using DNA gel viewer.
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3.7.3 Cell seeding and Co-transfection
HaCaT cells were seeded in a 6-well plate and allowed to reach confluency of
50-70%. Co-transfection of both gRNAs and donor plasmid was carried out in in
duplicate in 6 separate wells and utilized according to the LipofectamineTM 3000
Reagent protocol from Thermo Fisher. On completion of this, the cells were incubated
for 2-4 days at 37 °C.

3.7.4 Cell passaging and colony selection
Forty-eight hours post-transfection, cells were passaged at a ratio of 1:10 and
allowed to grow every 3 days after passaging 7 times so as to dilute cells with episomal
donor vectors. On the 8th passage, cells were split into a 20 cm dish for colony selection
using puromycin selection. The cells were selected with puromycin (2 µg/ml) for 5 days
and media was changed every 2-3 days until well separated colonies were formed.

3.7.5

Analysis
Single colonies formed were selected from the 20 cm plates and then expanded.

Western blotting and immuno-dot blot assays were carried out to analyse genomic
editing results to determine and identify knockout of ASM in each selected colony.

3.7.5.1 Western blot
Growth media was discarded, and cells were washed with cold 1x PBS. Cells
from selected colonies were scrapped from culture plates and then RIPA buffer
containing protease inhibitor cocktail was added and incubated at room temperature for
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30 minutes with shaking at intervals. The samples were then centrifuged at 16,000 x g
for 15 minutes, and supernatants were transferred to a new tube. BCA assay was carried
out to determine the protein concentration and then 30 g of proteins was separated by
10% SDS PAGE run at 130 volts for 50 minutes. The proteins were then transferred
onto a nitrocellulose membrane using a semi-dry blot transfer for 35 minutes. The
membrane was blocked using 5% non-fat dry milk for 1 h and washed with 1x TBST 4
times for 5 minutes each. Membrane was probed with anti-ASM antibody (LifeSpan
BioSciences, Inc) (1:2000) overnight, and then with goat anti-rabbit antibody (1:10000)
conjugated with HRP for 1 h. ASM bands were detected using SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher scientific) and the images were taken
with BioRad imaging system. The membrane was later stripped using a stripping buffer,
incubated at 80 °C for 5 minutes, washed, blocked and re-probed using anti-β-actin
antibody overnight, as a loading control.

3.7.5.2

Immuno-dot blot assay

To lyse the cells, media from 96-well plate were poured off into a large beaker in
the hood and 100 µl of PBS was added to each well of the 96-well plate to briefly rinse
the cells. Trypsin-EDTA (40 µl of 0.25%) was added to each well of the 96-well plate
and incubate plated in the 37°C incubator until the cells rounded up and began coming
off the plate. Cell culture medium (160 µl) was then added to each well of the 96-well
plate. The cell suspension was transferred to a new 96-well, clear, flat-bottom, nonsterile plate. Add 100 µl culture medium to the remaining cells and place back into the
incubator (cells will re-attach and start to proliferate). Spin the 96-well plate in a
swinging bucket rotor for 5 min at 1500 rpm to pellet the cells. Then, pour off the media
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from the plates. Next, we added 100 µl of cold PBS to each well of the plate to rinse
the cells and spin again for 5 min at 1500 rpm to pellet the cells. 40 µl of RIPA buffer
was added to each well of the plate. We next incubated the plate on ice for 10 min and
occasionally tap the side of the plate to facilitate cell lysis. We next added 160 µl of
cold PBS to each well of the plate and spin the plate at 3250 rpm (max speed) for 5
min. Then transfer the 200 µl soluble lysate to a new 96-well plate.

For protein immunoblotting, we cut a piece of nitrocellulose membrane to the
same size as the Bio-Dot SF filter paper (Bio-Rad #1620161) and soaked the
nitrocellulose membrane and two pieces of Bio-Dot SF filter paper in 1X PBS. Next,
we assembled the dot blot apparatus and tightened the screws and used the vacuum to
draw any PBS down from the membrane. Next, we turned off the vacuum and removed
the flask plug to release the pressure and completely stop the vacuum. Next, we loaded
200 µl of PBS into each well of the dot blot apparatus. Next, 100 µl of cell lysate was
added to the appropriate well. Vacuum (not at full pressure) was used to draw the lysate
down through the membrane. After turning off the vacuum and we removed the flask
plug and added 200 µl of PBS to each well to wash the membrane and then used the
vacuum to draw the PBS through the membrane. We disassembled the dot blot
apparatus and carefully remove the nitrocellulose membrane and place on a piece of
dry filter paper. Place the membrane into the -80°C incubator for 30 min to dry the
membrane. The membrane was wetted with water and then stained with Ponceau dye.
Excess dye off was rinsed off with water and then we took a picture of the Ponceaustained membrane and washed the membrane 3-4 times with TBST to completely
remove the Ponceau dye. We then blocked the membrane for 30 min in 5% milk in
TBST and was probed with Anti-ASM antibody.
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3.7.5.3

MVP release
HaCaT cells systematically edited using CRISPR Cas9 were also analysed by

MVP release upon exposure to stressor as follows:
Table 5: Treatment of CRISPR Cas9 edited cells for MVP analysis
Treatments

Concentration/ Time

Sham

Ø

Vehicle

DMSO

CPAF

100 nM

C2-ceramide

20 M

Dihydroceramide

10 M

UVB

3.6 KJ/m2

Thermal burn (90°C)

8 secs

After 4-hour incubation time, supernatant was collected for each group.

3.7.5.4

MVP Isolation and Analysis:

MVPs were isolated and quantified as described above.

3.8

Flow cytometry
Cells were treated with or without CPAF and fixed for 10 minutes in 4%

paraformaldehyde (w/v) in PBS. The cells were washed using cold 1x PBS and then
blocked using 1% BSA for 30 minutes. The cells were washed and incubated with rabbit
polyclonal ASM antibody in 1:50 in PBS for 45 minutes. This was followed by washing
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the cells and incubating with FITC-labelled goat anti-rabbit secondary antibody for 45
minutes. The cells were washed and analysed using BD accuri C6 flow cytometer
system (BD Biosciences).
3.9

Determining the genomic targeting efficiency of Cas9/gRNA with T7
Endonuclease
Genomic DNA from transfected cells were purified with Qiagen genomic DNA

purification kit and DNA concentration was measured using PicoGreen quantification
protocol adapted for Quant-iT PicoGreen kit.
Forward Primer: GACTCCTTTGGATGGGCCTG
Backward Primer: CTACAATCCATCACTGAGTTTGCTC
Table 6: PCR conditions
Initial duration

94°C

1 min

Denaturation

94°C

30 sec

Annealing

55°C

30 sec

Extension

72°C

1 min

Final extension

72°C

7 min

Hold

4°C

35 cycles

50 µl PCR was set up accordingly and PCR conditions used a PCR thermocycler
(Thermo Fisher Scientific). The PCR product was purified using PCR purification kit
(Invitrogen). The DNA concentration was again quantified with PicoGreen. T7
Endonuclease 1 digestion reaction was set up for denaturation/hybridization using 200
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ng DNA, 2 µL 10X NEBuffer2 and the final volume was brought up to 19 µL using
distilled DNase free water then put in a thermocycler at stated condition (from NEB
website). 1 µL of T7 Endonuclease 1 was added to the PCR products and was incubated
for 15 minutes at 37 ᴼC. The reaction was stopped by adding 0.75 µL of 0.5 M EDTA.
4 µL of 6X loading dye was added to the PCR product and ran on 2% agarose gel
stained with ethidium bromide.

3.10 ASM translocation
3.10.1 Cell seeding
Growth media was added to 6-well plates and sterilized glass cover slip was
added to each well using sterilized forceps. HaCaT cells added in a ratio 1:100 to growth
media, incubated for 1-2 days to attach and grow on the glass cover slip.

3.10.2 Treatment
The cells were treated with or without CPAF and incubated for either 10 or 30
minutes, primary antibody alone and secondary antibody only.

3.10.3 Immunofluorescence
Upon completion of duration of incubation, cells on the cover slips were rinsed
briefly in 1x PBS containing 0.1 Triton X- 100. The cells were fixed using 4%
paraformaldehyde in 1x PBS for 10 min at room temperature and washed using cold 1x
PBS three times. Each cover slip was then blocked to prevent nonspecific binding of
antibodies using Normal Horse Serum (Jackson ImmunoResearch) in ratio 1:50 to 1x
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PBS for 30 minutes in a humidifying chamber at room temperature. It was then washed,
and cells were incubated in primary antibody Anti-ASM antibody at a ratio of 1:100
and incubated for 1 h at room temperature. Cells were washed and incubated using
secondary FITC-anti Rabbit at a ratio of 1:100 in the dark for 30 minutes. The cells
were then washed with cold PBS three times and a drop of mounting medium
conjugated with DAPI was added to microscope slide and the glass cover slips were
mounted and images were taking using Cytation 5 Cell Imaging Multi-Mode Reader
(BioTek) and then stored in the dark.
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CHAPTER 4: RESULTS

4.0

4.1

In vitro studies

Dose response effect of ethanol mediated MVP release in HaCaT cells
To determine the dose response effect of EtOH on HaCaT cells, different doses

of EtOH (0.1, 0.5, 1, 2.5 and 5%) were used treat keratinocyte cells and were incubated
at 37°C for 4 hours (Figure 2). As shown in Figure 2, HaCaT cells responded to
exogenous EtOH with increased levels of MVP over baseline levels. Figure 3 shows
phase contrast images of HaCaT cells and increased dose of EtOH at 2.5 and 5%
treatment was toxic to the keratinocyte cells.

3.010 09

2.010 09

**
ns

1.010 09

Figure 2: Dose response of EtOH in keratinocyte HaCaT cells
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Dose Response of ETOH in HaCaT cells

HaCaT cells had either no treatment (NT), or 0.1%, 0.5%, 1%, 2.5% and 5% EtOH.
Cells where then incubated for 4 hours. The data represented are mean ± SEM MVP
concentration per 100,000 cells (average from 3 independent experiments, n=6).
Groups were compared using one-way ANOVA.

Differences in samples were

considered significant if the P value was less than 0.05. P<0.05 (*), P<0.01 (**), and
P<0.001 (***).

Figure 3: Phase contrast images of the dose response of EtOH treated Keratinocytes
Phase contrast images taken using Cytation 5 Cell Imaging Multi-Mode Reader
(BioTek) showed toxicity to the cells as cell lift-off cell culture plates with an increase
in level of EtOH after 2 hours.

4.2

EtOH induced MVP release in NTERTs and Normal Human Fibroblasts
The next studies sought to define if other cell types found in skin would respond

to exogenous EtOH with increased MVP release. To that end, NTERT cells and
Normal Human Fibroblasts (NHF) were treated with 1% EtOH (Figures 4 and 5
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respectively) to determine the concentration of MVP release in both cell lines. These
studies suggest that HaCaT cells are not unique in responding to exogenous EtOH with
increased levels of MVPs.

3.010 10
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MVP Release from NTERT Cells
After 4 Hour Incubation

Figure 4: MVP release in NTERT cell on treatment with 1% EtOH
NTERT cells had either no treatment (NT), or 1% EtOH and cells where then incubated
for 4 hours. The data represented are mean ± SEM MVP concentration per 100,000
cells (number of samples in each group, n=4). Groups were compared using an
unpaired t-test. Differences in samples were considered significant if the P value was
less than 0.01 (**).
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Figure 5: MVP release in Normal Human Fibroblast (NHF) cell on treatment with 1%
EtOH
NHF cells had either no treatment (NT), or 1% EtOH and cells where then incubated
for 4 hours. The data represented are mean ± SEM MVP concentration per 100,000
cells (number of samples in each group, n=4). Groups were compared using unpaired
t-test. Differences in samples were considered significant if the P value was less than
0.01 (**).

4.3

MVP release from HaCaT cells after exposure to EtOH and TBI
The next studies sought to define if combining EtOH and TBI could result in

augmented MVP release. As shown in Figure 6, HaCaT cells treated with 1% EtOH
generated increased levels of MVP. Moreover, thermal burn injury for 8 and 45 sec
induced MVP release at 4h compared to no treatment. Importantly, combining EtOH
and TBI resulted in increased levels of MVP release as compared to EtOH or burn
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treatments alone (Figure 6). These studies suggest that EtOH can augment burn injurymediated MVP release. The amounts of MVP appear additive from the individual
stimuli.

Figure 6: MVP release from HaCaT cells upon exposure to ethanol and burn
HaCaT cells had either no treatment (NT), or 1% EtOH for 30 min followed by 8 and
45 second thermal burn injury. Cells where then incubated for 4 hours. The data
represented are mean ± SEM MVP concentration per 100,000 cells (average from 3
independent experiments). Groups were compared using one-way ANOVA. Differences
in samples were considered significant if the P value was less than 0.05. P<0.05 (*),
P<0.01 (**), and P<0.001 (***).
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4.3.1 Effect of imipramine on EtOH- and TBI-induced MVP release in HaCaT cells
To determine whether the pharmacologic ASM inhibitor imipramine will
attenuate EtOH and EtOH + TBI induced MVP release, HaCaT cells were treated with
or without imipramine (Figure 7). Imipramine did not have a significant effect on
EtOH-induced MVP release. However, imipramine significantly decreased MVP
release when exposed to EtOH + TBI. These studies suggest the possibility that
imipramine modulates MVP release in response to TBI but not EtOH.
.

Figure 7: Imipramine blocks MVP release
HaCaT cells were either exposed to no treatment or imipramine for 30 minutes. Cells
were then exposed to media alone or 1% EtOH for an additional 30 min. Cells were
then treated with TBI as previously outlined. Cells were then incubated for 4 hours.
The data represented are mean ± SEM MVP concentration per 100,000 cells (average
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from 2 independent experiments). Groups were compared using one-way ANOVA.
Differences in samples were considered significant if the P value was less than P<0.01
(**), and P<0.001 (***) and ns denotes no significant.

4.4

Effect of EtOH and UVB on MVP release
We also tested the effect of EtOH and UVB (3,600 J/m2) on HaCaT cells (Figure

8). There is a significant increase in UVB- or EtOH-induced MVP release, but no
significant increase in MVP release was found in combining EtOH + UVB compared
to UVB alone.

Figure 8: MVP release from HaCaT cells upon exposure to EtOH and UVB
HaCaT cells underwent either no treatment (NT) or 1% EtOH for 30 minutes. The
cells were then treated with our Philips UVB source for 12 minutes (3600 J/m2). Cells
where then incubated for 4 hours. The data represented are mean ± SEM MVP
concentration per 100,000 cells (average from 2 independent experiments). Groups
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were compared using one-way ANOVA. Differences in samples were considered
significant if the P value was less than 0.05. P<0.05 (*), and ♯ denotes no significant.

4.5

EtOH stimulates the release of MVPs in vivo
To test the effect of EtOH induced MVP release in vivo, WT and PAFR-KO

mice were utilized to observe the effects of combining TBI and EtOH on keratinocyte
and systematic release of MVP from epithelial cells, and role of the PAFR. Using a
previously published model [1], mice were treated IP with 20% EtOH and exposed to
thermal burn injury for 8 seconds on their back. Burn skin samples were compared to
NT skin (Figure 9). Skin biopsies were taken, and cardiac perfusion was done to collect
blood. MVP from analyzed punch biopsies showed that WT mice had a significant
MVP release on after exposure to TBI and E+TBI compared to skin biopsies taken
PAFR KO mice (Figure 10). Furthermore, serum from treated WT mice was significant
when mice were treated with ethanol, burn and E+B (Figure 11). Collectively, these
experiments suggest that TBI of intoxicated mice results in increased levels of MVP in
both skin and serum. Moreover, this effect appears to be dependent upon the PAFR.

Figure 9: Image of murine back skin treated with TBI
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The figure above are skin from A) NT and B) thermal burnt skin WT mice. There is
profound redness or inflammation seen in the latter than the former.

Figure 10: MVP release in murine skin biopsies after 2h treatments
MVP release from WT and PAFR-KO mice punch skin biopsies were measured and
analysed using NTA software version 3.0. The data above are mean ± SEM MVP
concentration (representative of skin biopsies from 6 mice, from 3 separate
experiments). Groups were compared using one-way ANOVA. Differences in samples
were considered significant if the P value was less than P<0.01 (**), ns denotes no
significance.
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Figure 11: MVP release in mouse sera following EtOH exposure and TBI
MVP release into WT and PAFR-KO mice serum from the experiment outlined in
Figure 10 were measured and analysed using NTA software version 3.0. The data above
are mean ± SEM MVP (representative of serum from 6 mice, from 3 separate
experiments). Groups were compared using one-way ANOVA. Differences in samples
were considered significant if the P value was less than 0.05. P<0.05 (*), P<0.001
(***), and ns denotes no significance.

4.6

ASM translocation
To determine whether ASM was targeted to the plasma membrane in response

to cell stress, HaCaT cells were treated with CPAF for a duration of 10 and 30 minutes
and then ASM localization was determined by indirect immunofluorescence
microscopy (Figure 12). Cells stained after a 10-minute exposure showed what could
be a potential early formation of ASM on the plasma membrane. In contrast, ASM
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staining in the vehicle-treated cells was not well-defined. After 30 minutes of
treatments, the fluorescence from the stained cells in both groups decreased.

Figure 12: Translocation of ASM to the plasma membrane
HaCaT cells were treated with CPAF or veh (0.1% EtOH) and stained for ASM.
Images were taken using Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). ASM
is indicated in green and DNA in blue.

4.7

Analysis of potential ASM-KO HaCaT cells
The next studies were designed to create a model of HaCaT cells which lack ASM

expression. This novel model could have use in determining if ASM knockout using
CRISPR/Cas9 will suppress the PAF system-dependent release of MVP upon exposure
to UVB, EtOH, thermal burn injury in the HaCaT- keratinocyte cell line. These studies
are critical to confirm findings generated using the pharmacologic inhibitor
imipramine. Transfected colonies were screened using immunoblot and MVP release
analysis. To show whether ASM expression is absent in selected clones of HaCaT cells
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transfected with ASM guide RNAs G1 and G2, Western blot was carried out (Figure
13). For HaCaT, three selected clones from G2, one G1 and HaCaT cells were used as
a positive control. ß-actin was the loading control for each lysate. As shown in Figure
12, G25B and G25A had only a partial reduction in ASM protein expression. The graph
shows relative ASM protein expression normalized to actin. Immuno-dot blot was
carried out by screening 96 different clones (Figure 14). The figure showed that all
clones still expressed ASM protein.
.

Figure 13: Western blot analysis of ASM expression in keratinocytes and selected
colonies
Western blot screening of colonies showing expression of ASM protein. Four different
puromycin-resistant clones were analysed using their proteins lysates following
transfection with G1 and G2 Guide RNA and CRISPR-Cas9 genome editing. In the
graph, the ASM protein was normalized to actin.
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Figure 14: Immuno-dot blot analysis of ASM expression in 96 selected colonies
Immuno-dot blot analysis of CRISPR Cas9 transfected cells. Ninety-six individual
clones were screened for ASM protein expression.

4.8

MVP analysis of potential ASM-KO cells.
HaCaT cells were used as a positive control to compare the release of MVP in

potential ASM-KO cells, G12B and G25A (Figure 15 and Figure 16). The treatment
had 7 groups, NT, Vehicle (DMSO), CPAF, UVB, BURN, C2- ceramide and di-C2. It
was observed that the basal level of G1 was lower compared to WT. UVB, treatment
caused increase MVP release. Exogeneous C2-ceramide also increase MVP release
since ceramide is essential for budding of MVP from plasma membrane. However,
BURN and di-C2 treatment caused greater MVP release in comparison to the basal G1.
However, G2 (as shown in Figure 13) responded to all treatments thus releasing MVP
in comparison to HaCaT.
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Figure 15:MVP release from HaCaT and ASM KO HaCaT (G1) cells
The ASM gRNA 1 (G1)-transfected cell line G25A had a lower basal level of MVP
release, but still responded to UVB exposure and thermal burn injury. The data
depicted are mean ± SEM MVP concentration per 100,000 cells.
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Figure 16: MVP release from HaCaT and ASM KO HaCaT (G2) cells
MVP release from gRNA 2 (G2) (pooled from figure2 G25B) transfected cells
responded to UVB and thermal burn on exposure. The data depicted are mean ± SEM
MVP concentration per 100,000 cells.

4.9

Flow cytometry
To detect ASM in the plasma membrane upon exposure of HaCaT and potential

ASM-KO cells to CPAF and UVB. On exposure to stressors, we identified that both
HaCaT and G1 had similar florescence intensity (Figure 17), thus suggesting that ASM
is still present in HaCaT cells transfected with G1 gRNA (pooled from Figure 13)
targeting ASM.

Figure 17: Flow cytometry analysis of ASM fluorescence intensity in HaCaT and G1
cells
Images A &B shows the detection of FITC-stained ASM in G1 and HaCaT cells with
no antibody (ab), secondary antibody alone and primary and secondary ab. Image C
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shows the combination of both G1 and HaCaT cells treated with no ab, CPAF and
UVB.

4.10 Determining genomic targeting efficiency of Cas9/gRNA with T7 Endonuclease
1
To determine the Cas9 targeting efficiency of the ASM gRNAs, we purified
genomic DNA 24 hours following transfection of HaCaT cells with plasmids
expressing Cas9 and either the G1 or G2 ASM gRNAs. We then used PCR primers to
amplify the region of the ASM locus targeted for editing by Cas9 and the gRNAs. The
PCR products were then heated and allowed to re-anneal to enable heteroduplex
formation. The enzyme was then treated with T7 endonuclease which recognizes DNA
mismatches present in heteroduplexes and cleaves the DNA. Thus, if the Cas9 enzyme
was efficiently targeted by the guide RNAs to the ASM locus for genome editing, then
PCR amplification of the locus should yield a mixture of products containing wild-type
and mutant sequence that form a heteroduplex that can be cut by T7 endonuclease. PCR
amplification of the ASM locus from genomic DNA of cells transfected with both
gRNAs yielded an expect product of 371 bp (Figure 18). If the gRNAs efficiently
targeted Cas9 to the ASM locus, then treatment with T7 endonuclease should yield
products of G1 165 bp and 206 bp for the G1 gRNA and approximately 125 bp and 246
bp for the G2 gRNA. However, T7 endonuclease failed to generate DNAs of the
expected sizes (Figure 19). These results indicate that the ASM gRNAs were not
effective at targeting the Cas9 nuclease to the ASM locus for genome editing.
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Figure 18: PCR amplification of the ASM
Amplification of the ASM locus from genomic DNA of cells transfected with both gRNAs
(G1 and G2) yielded an expect product of 371 bp.

Figure 19:Genomic targeting efficiency of Cas9/gRNA with T7 Endonuclease 1
PCR result of using T7 to detect mutation at ASM target site. The resultant sizes of T7
endonuclease product G1 was approximately 206 bp. and G2 was approximately 246
bp. The cleaved sizes (165 bp and 125 bp) in both sample DNA was not observed from
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the images taken from the agarose gel thus suggesting Cas9/gRNA could be inefficient
in cutting the site of interest.

4.11

Comparison of MVP release in WT and ASM-KO NMF
Given that we were unsuccessful in generating HaCaT ASM KO cells, we

sought an alternative strategy. We therefore derived primary fibroblasts (normal mouse
fibroblasts, NMF) from the skin of new-born ASM-knockout mice for our studies.
Fibroblast cells derived from both WT and ASM KO mice were treated with VEH,
imipramine (IMI), CPAF, UVB, BURN, C2-ceramide and di-C2 (Figure 20) and
incubated at 37°C for 4 hours. As shown in Figure 20, no significant difference in MVP
release was observed between any treatment groups in the WT and ASM-KO NMF.
Given that we found that fibroblasts did not respond positively to the various stressors,
these studies indicate that fibroblasts may not be not an appropriate model.

Figure 20: MVP release from NMF WT and ASM-KO primary skin fibroblasts
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MVP release from NMF WT and ASM KO NMF has no significant difference in all
treatment groups. The data represented are mean ± SEM MVP concentration per
100,000 cells (from 2 independent experiments). Groups were compared using two-way
ANOVA. Differences in samples were considered significant if the P value was less
than 0.05.
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CHAPTER 5: DISCUSSION AND CONCLUSIONS

Ethanol is a known intoxicant. Both ethanol and ceramide activate ROS
formation in part by activating apoptotic pathways, thus indicating the involvement of
ceramide in ethanol-mediated apoptosis [54]. Thermal burn injury causes local effects
at the sites of injury and could lead to systemic effects. In vivo studies using WT mice
show that MVPs are found not just only in skin taken from affected the area but also in
the serum which could possibly be shed from the epidermis. The mechanism by which
this occurred is not clear, however, but the shedding of MVPs after exposure to stimuli
is associated with cell to cell communication and this could be a possible means. To
test if MVP release is dependent on PAFR, we exposed PAFR-KO mice to similar
treatment to the WT mice. In PAFR-KO mice, there was no significant release of MVPs
after TBI or EtOH exposure, which suggests that PAFR is involved in the generation
of MVP in vivo.
In vitro studies using HaCaT cells demonstrated an increase in MVP release after
exposure to EtOH alone. Combining EtOH with TBI resulted in an additive effect on
MVP release. However, UVB + EtOH did not appear to exert greater effects than UVB
alone. Treatment of HaCaT cells exposed to EtOH and TBI with imipramine resulted
in a significant decrease in MVP release. However, treatment with imipramine had no
significant effect on EtOH induced MVP release.
Attempt of knocking out ASM in HaCaT cells using CRISPR Cas9 genomic
editing was not successful on analyzing several colonies using immuno-dot blot. When
HaCaT cells transfected with Cas9 and ASM gRNAs were exposed to stressors that
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induce MVPs and compared to normal, un-transfected HaCaT cells, the results obtained
showed that the transfected cells responded to these stressors in a similar manner as in
normal HaCaT cells. Commercially generated CRISPR Cas9 ASM-KO HAP1 cells
obtained also responded to stressors in a similar manner as WT HAP1 cells. Thus, using
two different cell types (HaCaT and HAP1) and three different guide RNAs (all
targeting exon 1 of ASM), the CRISPR Cas9 failed to generate ASM-KO cells with
defects in MVP release. Flow cytometry was also carried out to detect presence of ASM
in HaCaT and cells transfected with CRISPR Cas9 complex upon treatment with CPAF
and UVB. Result obtained showed similar florescence intensity detected in HaCaT
cells.
To define the possibility that the gRNAs were not appropriate, we conducted
direct testing using T7 endonuclease to determine the cutting efficiency of these gRNA.
Results obtained showed inefficient gRNA cutting. We believe that this provides an
explanation for why we were unable to effectively knockout the gene of interest in this
study.
We also investigated the translocation of ASM to the outer leaflet of the plasma
membrane at time 10 and 30 minutes incubation period after treatment with or with
CPAF. ASM-stained cells treated with CPAF at 10 mins showed some spots (believed
to be ASM) on the plasma membrane of the cells, while none were seen in the vehicle
treated FITC staining. We also observed that the immunofluorescence staining by FITC
had diminished at 30 minutes. This resulted suggest that the translocation of ASM from
nucleus to the membrane occurs rapidly on exposure to various stimuli. Supporting the
study carried out by Li et al [37].
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The first limitation in this study is that the gRNAs were not efficient in cutting
and deleting the gene of interest (ASM) in HaCaT cells. A specific and precise ASMKO could support the idea of imipramine inhibited MVP release on exposure to UVB,
BURN and CPAF. Use of confocal image will give a more defined image of ASM
translocation to the outer leaflet of the membrane. The measurement of ASM activity
using scintillation counter/HPLC to measure the production of ceramide would have
also helped in this study.
Our obtaining ASM KO mice will assist in future studies defining the role of
ASM in MVP release. Unfortunately, these mice have just come out of quarantine and
we are only now able to grow primary cells from KO mice. Of importance, these mice
are bred using heterozygous males and females which limits our ability to generate
large numbers of mice.
Our current model is that upon environmental stressors, PAF is produced which
then induces a rapid ASM translocation to the cell membrane. This process then
facilitates MVP formation and release through ceramide formation. Our study provides
evidence that ethanol induces MVP release in keratinocyte cells, skin, and serum from
mice. It also proves that PAFR is necessary in the release of MVP on exposure to TBI.
One area which will be of importance to assess is if the MVP found in skin and serum
in mice are from keratinocytes. Our laboratory is currently screening keratinocytespecific markers and it is our hope to be able to generate one to address this important
question.
In summary, the present studies have unlocked a new effect of alcohol, namely,
that EtOH can generate MVP. Since the role of MVP in skin-derived injury is
unknown, this finding is of unclear significance at this time. However, an understanding
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of how MVP production is regulated, such as possibly via ASM, could provide
important tools to dissect the role of MVP in skin responses.
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